Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs
Клинические разработки химиотерапевтических нанопрепаратов: полимеры и липосомы для доставки камптотецинов и препаратов платины (II)
2013-01-17
SCID: 54.1/auds2z9d
Discuss with AI
camptothecin deliverychemotherapeutic nanomedicinescisplatin deliveryliposomal drug deliverypolymeric drug delivery
Figures from the paper
Abstract (AI)
Abstract For the past 40 years, liposomal and polymeric delivery vehicles have been studied as systems capable of modulating the cytotoxicity of small molecule chemotherapeutics, increasing tumor bearing animal survival times, and improving drug targeting. Although a number of macromolecular‐drug conjugates have progressed to clinical trials, tuning drug release to maintain efficacy in conjunction with controlling drug toxicity has prevented the clinical adoption of many vehicles. In this article, we review the motivations for and approaches to polymer and liposomal delivery with regard to camptothecin and cisplatin delivery.WIREs Nanomed Nanobiotechnol2013, 5:130–138. doi: 10.1002/wnan.1209 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Key Findings
1
Clinical translation of many nanomedicine vehicles remains limited because achieving effective drug release while controlling systemic toxicity is difficult.
2
Macromolecular drug conjugates for chemotherapeutic delivery have advanced to clinical trials, particularly for camptothecins and cisplatin.
3
Polymeric and liposomal vehicles have been investigated for approximately 40 years to modulate chemotherapeutic cytotoxicity, improve tumor targeting, and extend survival in tumor-bearing animals.
4
The review examines design motivations and delivery strategies for polymeric and liposomal systems carrying camptothecin and platinum(II) drugs.
Research Object
Polymeric and liposomal delivery vehicles for camptothecin and cisplatin
Research Subject
Clinical development, drug-release control, cytotoxicity modulation, toxicity management, and tumor targeting of these chemotherapeutic nanomedicines
Publication Details
Publication Date
2013-01-17
Journal
Publisher
ISSN
Cited by
50
Access Type
Author Information
Download PDF
Subscribe to digest